Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy

Glioblastoma multiforme (GBM) is the most common intracranial cancer but despite recent advances in therapy the overall survival remains about 20 months. Whole genome exon sequencing studies implicate mutations in the receptor tyrosine kinase pathways (RTK) for driving tumor growth in over 80% of GB...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Avadhut D., Loilome, Watcharin, Siu, I-Mei, Tyler, Betty, Gallia, Gary L., Riggins, Gregory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3462750/
https://www.ncbi.nlm.nih.gov/pubmed/23056179
http://dx.doi.org/10.1371/journal.pone.0044372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3462750/
https://www.ncbi.nlm.nih.gov/pubmed/23056179
http://dx.doi.org/10.1371/journal.pone.0044372

Ejemplares similares